🚨 Registration is OPEN! 🚨 Join us March 8–11, 2026 in Orlando for the #MDAConference, the leading global event for neuromuscular care & research. 🌍🧬 🔗 Register now: www.mdaconference.org #MDA #MuscularDystrophy #neuromuscular

🚨 Just launched: our expert interview collection from AAIC 2025! From novel blood-based biomarkers to tau-targeting therapies and scalable digital tools, top researchers and clinicians shared insights into where Alzheimer care is headed. 🧠 Take a look→ www.neurologylive.com/view/aaic-20...

🧠🤔 In our Q&A, MIT’s Daniel Freedman, PhD, explains how Openwater’s Open-LIFU is enabling precise deep-brain access for studying how the conscious experience arises from brain activity, exploring treatments for pain, depression, and more. Read now: www.neurologylive.com/view/openwat...

🚨FDA has approved fremanezumab (Ajovy) as the first anti-CGRP preventive treatment for pediatric episodic migraine, expanding care options for children and adolescents aged 6 to 17. Approval was supported by phase 3 SPACE study results. 📰Read more now: www.neurologylive.com/view/fda-app...

🧠 #AAIC25: ABvac40, a developing Alzheimer vaccine from Grifols, showed a significant reduction in cognitive decline in a phase 2 trial, and all met primary endpoints with no significant safety concerns 👏 Read more now: www.neurologylive.com/view/alzheim...

🧠 At #AAIC25, Sharron Gargosky, PhD, shared promising early data from Spinogenix’s phase 2 trial of SPG302 in #AD. The synaptogenic small molecule showed early signs of cognitive improvement and was well tolerated over 28 weeks 👏 Read more now: www.neurologylive.com/view/finding...

🧠 As patients grow up, care must grow with them, and support makes all the difference. In this new feature, Susan Duberstein, MD, PhD, outlines how continuity of care, patient education, and psychosocial support can smooth this critical journey ❤️ Learn more: www.neurologylive.com/view/the-tra...

The EMA’s CHMP has issued a negative opinion on the conditional marketing authorization for Elevidys, Sarepta/Roche’s gene therapy for DMD, citing missed primary endpoints in the EMBARK trial 🧬🤔 💻Read more: www.neurologylive.com/view/ema-iss...

New in hypersomnia research: In Ep. 4 of our SLEEP 2025 series, experts Eric Olson, MD, & Anita Shelgikar, MD, discuss the phase 2 Vibrance-3 trial of orexin-2 agonist ALKS 2680, presented at the #SLEEP2025 meeting 😴 📲Watch now: www.neurologylive.com/view/vibranc...

Major neurology trial readouts expected in 2H 2025 may redefine standards of care. Check out our curated list, including PERSEUS (tolebrutinib in PPMS) and azetukalner (for focal seizures), for insights into next-gen therapies 👀 📲Read now: www.neurologylive.com/view/eyeing-...

🧠💻 Can AI help identify cardiovascular risk in patients with #migraine? New data from #AHS2025 suggest AI-ECG tools, including atrial fibrillation prediction and delta age, may be effective for early detection of adverse vascular events. 🔗Read more now: www.neurologylive.com/view/explori...

FDA clears HyHub & HyHub Duo: new needle-free devices that simplify Hyqvia infusion for #CIDP, cutting down prep time and supplies. A major step forward in at-home or clinic-based treatment. The launch expected in late 2025 👀 📘Read more now: www.neurologylive.com/view/fda-cle...

Praxis Precision Medicines advances relutrigine for rare epilepsy, achieving FDA breakthrough status and promising results in ongoing clinical trials.👏 Read more now: www.neurologylive.com/view/breakth...

🎧🎙️ A special Mind Moments® episode with Stewart Tepper, MD, just dropped! Tune in as we unpack the FDA’s latest #migraine therapy approvals, STS101 and CT-132, and explore what these innovations mean for care, access, and outcomes. 🧠Listen now: www.neurologylive.com/view/special...

In this video, James Galvin, MD, MPH, explains how the CARM score uses 3 cognitive subtests and machine learning to estimate amyloid risk, helping clinicians assess whether cognitive impairment may be due to Alzheimer's and guide next steps in care 📽️ Watch now: www.neurologylive.com/view/overvie...

In episode 2 of our latest podcast, expert panelists break down the clinical signs, diagnostic strategies, and treatment options for #narcolepsy, offering practical insights for health care professionals new to the field ⚕️ 🎧 Listen here: www.neurologylive.com/view/video-n...

New VHA data show stroke risk in migraine isn’t limited to women or those with aura. At #AHS2025, Elizabeth Seng, PhD, discussed why sex differences matter in how we interpret and treat migraine 🧠 📹Watch now: www.neurologylive.com/view/using-v...

🎙️ Episode 145 of Mind Moments® is live! In this episode, Joyce Lee-Iannotti, MD, PhD, shares expert insights from the #SLEEP2025 joint meeting on emerging research at the intersection of #stroke, #sleep, and neurorestoration. 🧠 Listen now: www.neurologylive.com/view/episode...

FDA has approved Exablate Neuro for staged bilateral use in advanced #Parkinson disease. This noninvasive, MRI-guided ultrasound tech targets the brain with no cuts or implants. A safer step forward in neuro care. 🧠⚕️ Read more now: www.neurologylive.com/view/exablat...

📰FDA approves updated label for donanemab (Kisunla) with a new titration schedule to reduce ARIA risk in early-stage #Alzheimers. A promising step toward safer, more targeted anti-amyloid therapy. 🧠 🔗Read more now: www.neurologylive.com/view/fda-app...

🚨 The FDA has granted priority review to Denali Therapeutics’ tividenofusp alfa, a brain-penetrant therapy for Hunter syndrome (#MPSII). The decision represents the urgent need for treatments targeting neurological symptoms in patients. 🔗Read more now: www.neurologylive.com/view/fda-gra...

🔬 Dravet and Lennox-Gastaut may share trial headlines—but they’re clinically distinct. In our latest podcast episode, Dr. Joseph Sullivan breaks down how to differentiate them, what new research shows, and how trials are evolving. 🎧 Listen now: www.neurologylive.com/view/episode...

#BREAKING: The FDA has approved an expanded indication on @gehealthcare.bsky.social’s PET imaging agent Vizamyl to include both quantification of amyloid burden for patients with suspected Alzheimer disease (AD) and use in therapy monitoring. Details: www.neurologylive.com/view/fda-gre...

Today is Dravet Syndrome Awareness Day 🤲✨ Dravet syndrome affects ~1 in 15,000–30,000 births and requires early diagnosis for better outcomes and access to life-saving treatments. A piece from the @curedravet.bsky.social: 📖 www.neurologylive.com/view/changin...

Multiple sclerosis isn’t just relapses and mobility issues. Fatigue, cognitive dysfunction, and emotional well-being matter too. Dr. Taylor Hess breaks it all down in our latest episode for #WorldMSDay 🎙️ ➡️ www.neurologylive.com/view/episode...

#CMSC2025 abstracts are live! Time to plan your schedule for this week. abstracts.ijmsc.org/cmsc2025/abs...

📈 Can we make remyelination a reality for patients with MS? This expert-led roundtable breaks down where we are, what’s working, and what hurdles remain in one of the most ambitious efforts in MS care. 👥 Featuring: Ari Green, MD Paul Tesar, PhD Watch here: www.neurologylive.com/roundtable-d...

BREAKING: The @fda.gov has cleared Fujirebio's Lumipulse G p-tau217/ß-Amyloid 1-42 Plasma Ratio as the first blood test for the diagnosis of #AlzheimersDisease. Data from a study of nearly 500 participants with MCI backed the decision. www.neurologylive.com/view/fda-cle...

📢 New Educational Series: Advances in SMA Treatments Join experts Diana Bharucha-Goebel, MD, and Bakri Elsheikh, MBBS, FRCP, as they explore key updates in SMA care—from newborn screening and early intervention to treatment decision-making across age groups. www.neurologylive.com/roundtable-d...

Introducing our latest series with @curesma.bsky.social!✨ Throughout this week, we will be launching episodes from this 6-part series each day, giving clinicians insights on the latest updates in treatment decisions for SMA🧬👶🧑‍⚕️ Episode 1 is now live: neurologylive.com/view/sma-tre...

I loved participating in this (thank you for the invite @neurologylive.bsky.social ). I am always happy to talk about aging and Alzheimer's disease in people with Down syndrome! @ucimind.bsky.social @ucirvine.bsky.social!

#ICYMI: Last week, we launched a new episode of our Mind Moments podcast, featuring commentary from special guest @elizabethhead.bsky.social! We talked about Down syndrome and Alzheimer's, the emerging research around these conditions, and much more🎤 www.neurologylive.com/view/episode...

Thank you for helping us highlight this amazing group of people with Down syndrome and ensuring access to Alzheimer disease clinical trials.

💬 New #MindMoments podcast! How are clinical trials evolving for people with Down syndrome + Alzheimer’s? 🧠 @elizabethhead.bsky.social, shares updates on ABC-DS, anti-amyloid therapies, and why patient-centered care matters more than ever. 🎧 Listen now: www.neurologylive.com/view/episode...

#BREAKING: The @fda.gov has approved Johnson & Johnson’s nipocalimab, marketed as Imaavy, as a new treatment for adults and pediatric patients aged 12 years and older with generalized myasthenia gravis (gMG) who are anti-AChR or anti-MuSK antibody positive. 📲 www.neurologylive.com/view/fda-app...

Thanks for having me, @neurologylive.bsky.social! Appreciated the opportunity to discuss Kate Swider's work on Neurology Education in NP programs: www.neurology.org/doi/10.1212/...

🚨 At the 2025 AAN Annual Meeting, Dr. Chitra Venkatasubramanian advocated for aggressive BP lowering in spontaneous intracerebral hemorrhage (ICH) patients. #AANAM #AANAM2025 #BloodPressure Learn more @neurologylive.bsky.social: www.neurologylive.com/view/aggress...

#BREAKING: The FDA has approved an expanded indication for diazepam nasal spray (Valtoco; Neurelis), now allowing its use in children ages 2 to 5 for the treatment of seizure clusters, also known as acute repetitive #seizures. #FDAApprovals Read more: www.neurologylive.com/view/fda-exp...

#BREAKING: the FDA has made a major decision, approving Click Therapeutics' CT-132 as the first prescription digital therapeutic 📱💻⚕️for the preventive treatment of episodic migraine 🧠 in adults. More here on the decision: www.neurologylive.com/view/fda-app...

New data from #ADPD2025 📊 Cognito’s Spectris device showed 40 Hz brainwave activation + preserved corpus callosum structure in AD pts vs ADNI controls 🧠 Promising noninvasive tech for #Alzheimers. More here 👉 www.neurologylive.com/view/cognito...

👀 A glimpse into the future: From MEG and built-in MRIs to AI-powered diagnostics, @clevelandclinic.bsky.social's new neuro center is built to transform patient outcomes 🧠💡 Explore the innovation in our latest feature 📰: www.neurologylive.com/view/revolut...

Last Friday, we launched the latest episode of our Mind Moments podcast, featuring expert insight from special guest @danharrisonmd.bsky.social! In this 20-min convo, we discuss everything regarding NP education, including the changing roles of NPs: Listen in 🎙️ www.neurologylive.com/view/episode...

As part of #PurpleDay💜, we sat down with Luis Tornes, MD, of @baptisthealthjx.bsky.social to discuss some of the most pressing issues in epilepsy 🧠 care, myths surrounding seizures⚡, and innovations that are transforming patient outcomes💡 Read our Q&A: www.neurologylive.com/view/epileps...

#BREAKING: The FDA has accepted Sanofi’s regulatory submission for BTK inhibitor tolebrutinib as a potential treatment for patients with non-relapsing secondary progressive multiple sclerosis, assigning the agent a PDUFA target date of September 28, 2025. www.neurologylive.com/view/fda-acc...

Exclusive✨📰: We just launched a new piece highlighting key 2024 neurology guideline updates shaping clinical care across stroke, epilepsy, movement disorders, and more. These guidelines may impact your clinical practice👀 neurologylive.com/view/bluepri...

Happy Friday!☀️ Our latest Mind Moments podcast episode is live, featuring #epilepsy expert Sonal Bhatia, MD, FACNS, of @medunivsc.bsky.social! We talk Purple Day💜, advances in epilepsy care, transition to adulthood, EMUs, and much more: Listen in: www.neurologylive.com/view/episode...

Late-breaking findings using data from the CAVS-MS study showed that nearly one-fifth of patients with atypical clinical symptoms or radiological-only presentation met the latest criteria for MS using the updated 2024 McDonald Criteria revisions. Details: www.neurologylive.com/view/applica...

The FDA has accepted Capricor's BLA for deramiocel, a potential therapy for DMD cardiomyopathy. With a PDUFA date of Aug 31, 2025, it could become the first cell-based treatment for DMD and the first approved for DMD cardiomyopathy. #Duchenne 📲 www.neurologylive.com/view/dmd-com...

#ICYMI: Yesterday, the @fda.gov approved the expanded use of eculizumab (Soliris; @alexionpharma.bsky.social) to include pediatric patients with myasthenia gravis, making it the first and only treatment for pediatrics with this condition. Read more: www.linkedin.com/posts/neurol...

Happy Friday! This morning, we launched a new episode of the Mind Moments pod featuring president and CEO of Project Sleep, @remrunner.bsky.social 🥳 Listen in: www.neurologylive.com/view/episode...